The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Nektar Therapeutics's revenues will increase 10.7% and EPS will remain in the red.
The average estimate for revenue is $26.2 million. On the bottom line, the average EPS estimate is -$0.44.
Last quarter, Nektar Therapeutics chalked up revenue of $23.0 million. GAAP reported sales were 28% higher than the prior-year quarter's $17.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.48. GAAP EPS were -$0.48 for Q1 compared to -$0.36 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 49.3%, 220 basis points worse than the prior-year quarter. Operating margin was -197.4%, 460 basis points better than the prior-year quarter. Net margin was -239.4%, much worse than the prior-year quarter.
The full year's average estimate for revenue is $193.8 million. The average EPS estimate is -$1.14.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 193 members out of 222 rating the stock outperform, and 29 members rating it underperform. Among 58 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 44 give Nektar Therapeutics a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Nektar Therapeutics is outperform, with an average price target of $12.25.
- Add Nektar Therapeutics to My Watchlist.